Marty J. Duvall

Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA.

Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA.

Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA.

Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA.